Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04053699 · ClinicalTrials.gov registry record
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
A clinical trial of Von Willebrand Diseases, sponsored by Octapharma.
- Completed
- Registry status
- 56
- Enrollment target
- 15
- Study locations
NCT04053699 is a study of Von Willebrand Diseases that has completed, run by Octapharma. The registered enrollment target is 56 participants, below the 727-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (92% lower). The trial reports 15 study locations across 2 states.
The verdict
NCT04053699, a study of Von Willebrand Diseases, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months. The data obtained will be used as a basis for historical comparisons with the bleeding and treatment pattern obtained from a clinical study on the efficacy of prophylactic treatment with a VWF/FVIII concentrate.
Conditions Studied
Interventions
- DRUG Von Willebrand Factor-Containing Product
Study Locations (15)
Other
- Republican Research Center for Radiation Medicine and Human Ecology - Homyel
- Specialized Hospital for Active Treatment of Haematological Diseases" EAD, Sofia - Sofia
- "UMHAT Sveta Marina" EAD. - Varna
- University Hospital Centre Zagreb - Zagreb
- Medical Centre Hungarian Defence Forces - Budapest
- Debreceni Egyetem Klinikai Központ, Regionális Haemophilia és Thrombophilia Központ - Debrecen
- University Clinical Center, Department of Internal Medicine, Hematology - Pécs
- Hotel Dieu de France Hospital - Beirut
- American University of Beirut Medical Center - Beirut
- Nini Hospital - Tripoli
- Federal State Budgetary Scientific Institution Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal - Kirov
- Morosovskaya Children Clinical Hospital, Moscow Health Department, Department of General Hematology with the Pathology of Hemostasis - Moscow
- State Institution "National Children's Specialized Hospital "OKHMATDYT" of the Ministry of Health of Ukraine," Center of Hemostasis Pathology - Kyiv
- Community Institution of Lviv Oblast Council "West-Ukrainian Specialized Children's Medical Center - Lviv
Georgia
- Children's Healthcare of Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2021-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04053699
The ClinicalTrials.gov registry entry for NCT04053699 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 727-participant average among 5 other Von Willebrand Diseases trials with a reported enrollment target (92% lower). The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Von Willebrand Diseases appearing as the primary indexed condition, and to 1 intervention - of which Von Willebrand Factor-Containing Product is the first listed.
NCT04053699 reports 15 study locations spanning 2 distinct geographic areas - top geographies include Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT04053699 about?
NCT04053699 is a clinical study titled "Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment". The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months. The data obtained will be used as a basis for historical comparisons with the bleeding...
What is the current status of trial NCT04053699?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2019-06-25. Estimated completion is 2021-01-31.
What conditions does trial NCT04053699 study?
This clinical trial studies the following conditions: Von Willebrand Diseases.
What interventions are being tested in trial NCT04053699?
The interventions under investigation include: Von Willebrand Factor-Containing Product (DRUG).
Who is sponsoring clinical trial NCT04053699?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04053699 being conducted?
This trial has 15 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
RECRUITING
-
Von Willebrand Factor in Pregnancy (VIP) Study
RECRUITING
-
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
RECRUITING · Phase 1
-
ATHN 9: Severe VWD Natural History Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.